Sumathi Reddy is the "Your Health" columnist at The Wall Street Journal, writing about all things health and medicine. Her columns cover everything from exercise and weight-loss drugs to cannabis and ...

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active ...

With more than 15 years of experience crafting content about all aspects of personal finance, Michael Benninger knows how to identify smart moves for your money. His work has been published by Intuit, ...

At 5 feet 11 inches and 138 pounds, Ali Balkey has always been thin. So it might seem surprising that the 41-year-old Dallas, Texas, real-estate investor says she has been taking a compounded version ...

Anvita Reddy (she/her) is a former assistant editor for PS Shopping. She has a passion for products and reviews home gadgets, cookware, tech, and more. Having dealt with acne as a teenager and into ...

We independently evaluate all of our recommendations. If you click on links we provide, we may receive compensation. The best 1-year CD rate right now is 4.75% APY from E*Trade from Morgan ...

WASHINGTON, DC – The Center for Strategic and International Studies (CSIS), a bipartisan, nonprofit policy research organization dedicated to advancing practical ideas to address the world’s greatest ...

Type 1 diabetes (also known as diabetes mellitus) is an autoimmune disease in which immune cells attack and destroy the insulin-producing cells of the pancreas. The loss of insulin leads to the ...

The Beatles have the most No. 1 hits among all acts in the chart's history, with 20. By Xander Zellner More than 32,000 songs have appeared on the Billboard Hot 100 in the chart’s history. Of those, 1 ...

India eases foreign investor access to commodity derivatives, widens scope of portfolio managers India on Thursday allowed foreign investors to trade in physically settled non-farm commodity contracts ...

Dr Reddy’s stocks: Nomura maintained its 'Buy' rating and Rs1,740 target price, based on 24x one-year forward EPS of Rs72.60. The stock trades at 17.4x and 14.6x FY28F and FY29F EPS, respectively. Dr ...